Literature DB >> 19020010

Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology.

Salvatore Oddo1, Antonella Caccamo, Bert Tseng, David Cheng, Vitaly Vasilevko, David H Cribbs, Frank M LaFerla.   

Abstract

The molecular alterations that induce tau pathology in Alzheimer disease (AD) are not known, particularly whether this is an amyloid-beta (Abeta)-dependent or -independent event. We addressed this issue in the 3xTg-AD mice using both genetic and immunological approaches and show that a selective decrease in Abeta(42) markedly delays the progression of tau pathology. The mechanism underlying this effect involves alterations in the levels of C terminus of heat shock protein70-interacting protein (CHIP) as we show that Abeta accumulation decreases CHIP expression and increases tau levels. We show that the Abeta-induced effects on tau were rescued by restoring CHIP levels. Our findings have profound clinical implications as they indicate that preventing Abeta accumulation will significantly alter AD progression. These data highlight the critical role CHIP plays as a link between Abeta and tau and identify CHIP as a new potential target not only for AD but for other neurodegenerative disorders characterized by tau accumulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020010      PMCID: PMC6671718          DOI: 10.1523/JNEUROSCI.2464-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  59 in total

1.  Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity.

Authors:  David X Medina; Antonella Caccamo; Salvatore Oddo
Journal:  Brain Pathol       Date:  2011-03       Impact factor: 6.508

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  The Proteasome and Oxidative Stress in Alzheimer's Disease.

Authors:  Vicent Bonet-Costa; Laura Corrales-Diaz Pomatto; Kelvin J A Davies
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

Review 4.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 5.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.

Authors:  Antonella Caccamo; Smita Majumder; Arlan Richardson; Randy Strong; Salvatore Oddo
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

Review 7.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

8.  5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.

Authors:  Jin Chu; Phillip F Giannopoulos; Carolina Ceballos-Diaz; Todd E Golde; Domenico Praticò
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

9.  mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.

Authors:  Antonella Caccamo; Andrea Magrì; David X Medina; Elena V Wisely; Manuel F López-Aranda; Alcino J Silva; Salvatore Oddo
Journal:  Aging Cell       Date:  2013-03-24       Impact factor: 9.304

Review 10.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.